Colorectal cancer (CRC) is the third most common tumour in men and the second in women,
accounting for 10% of all tumour types worldwide. Incidence is 25% higher in males and …

5-Fluorouracil remains a foundational component of chemotherapy for solid tumour
malignancies. While considered a generally safe and effective chemotherapeutic, 5 …

Background: Dihydropyrimidine dehydrogenase (DPD) deficiency screening is a pre-
therapeutic standard to prevent severe fluoropyrimidine-related toxicity. Although several …

Consensus guidelines exist for genotype‐guided fluoropyrimidine dosing based on variation
in the gene dihydropyrimidine dehydrogenase (DPYD). However, these guidelines have not …

Background: Plasma concentrations of fluoropyrimidine exhibit a wide interindividual
variability that depends mainly on the activity of dihydropyrimidine dehydrogenase, its major …

The current management of colorectal cancer liver metastasis (CRCLM) patients involves a
multidisciplinary approach, with surgical resection remaining the primary curative option …

Abstract Background 5-Fluorouracil (5-FU)-induced hyperammonaemic encephalopathy is a
rare but serious 5-FU adverse drug reaction (ADR). Given the growing number of cancers …

Purpose Standard dosages of fluoropyrimidine chemotherapy result in severe toxicity in a
substantial proportion of patients, however, routine pre-therapeutic toxicity prediction …

Although French genomic medicine is reaching a turning point in its history and the
implementation of genome sequencing in routine is being implemented as part of the France …

Objectives Genetic variants in the dihydropyrimidine dehydrogenase (DPYD) gene are
associated with reduced dihydropyrimidine dehydrogenase enzyme activity and can cause …